普拉克索缓释片治疗帕金森病非运动症状的临床观察

发布时间：2018-03-13 04:07

本文选题：帕金森病　切入点：非运动症状　出处：《山西医科大学》2017年硕士论文　论文类型：学位论文

【摘要】：目的:探讨盐酸普拉克索缓释片对于治疗帕金森病非运动症状的临床疗效。方法:收集2015年9月至2016年7月期间在山西医科大学第二医院及山西医学科学院神经内科首诊的101名帕金森病合并非运动症状病人的患病资料(运用MDS最新诊断标准)[11],用随机分配法分为多巴丝肼片组与普拉克索缓释片组,通过4周的药物滴定期和12周的药物维持期,并分别于2、4、6、8、10、14、16周进行随访观察,运用汉密尔顿焦虑及抑郁量表、帕金森病睡眠量表及认知功能等量表进行观察评分,同时记录不良反应,观察单用多巴丝肼片组与多巴丝肼联合普拉克索缓释片组在治疗非运动症状方面的疗效。结果:通过治疗观察,联合运用普拉克索缓释片组的患者在睡眠障碍,焦虑及抑郁等情绪障碍的治疗效果较单用多巴丝肼片组显著,差别存在统计学意义(P0.05),但在认知功能障碍、感觉异常和自主功能紊乱等方面,两组之间差别不存在统计学意义(P0.05)。结论:(1)普拉克索缓释片作为新型多巴胺受体激动剂,对于治疗帕金森病非运动症状,具有较好的疗效,明显改善患者焦虑、抑郁状态及睡眠障碍;(2)普拉克索缓释片对于治疗帕金森病运动症状同样具有较好的疗效;(3)针对帕金森病患者的治疗方案,药物拥有较好的安全性,可以长期使用。
[Abstract]:Objective: to investigate the clinical efficacy of Praxol hydrochloride sustained-release tablets in the treatment of non-motor symptoms of Parkinson's disease. Methods: from September 2015 to July 2016, we collected nerves from the second Hospital of Shanxi Medical University and the Shanxi Academy of Medical Sciences. The clinical data of 101 patients with Parkinson's disease and non-motor symptoms (using the latest diagnostic criteria of MDS) were randomly divided into two groups: dobutazide group and Praxol sustained-release tablet group. The patients were followed up for 4 weeks and 12 weeks, and followed up for 16 weeks, respectively. Hamilton anxiety and depression scale, Parkinson's disease sleep scale and cognitive function scale were used to observe and score. At the same time, adverse reactions were recorded to observe the efficacy of dobutazid alone and combined with praxol sustained-release tablets in the treatment of non-motor symptoms. The results of treatment of sleep disorder, anxiety and depression in patients with sustained-release tablets combined with Praxol were significantly higher than those in the group treated with dobutazide alone. The difference was statistically significant (P 0.05), but in cognitive dysfunction, there was no significant difference between the two groups in the treatment of sleep disorder, anxiety and depression. There is no significant difference between the two groups in terms of sensory abnormality and autonomic dysfunction. Conclusion: as a new dopamine receptor agonist, Platesol sustained-release tablet has a good effect on the treatment of Parkinson's disease with non-motor symptoms. Paxol sustained-release tablets were also effective in the treatment of motor symptoms of Parkinson's disease. It can be used for a long time.
【学位授予单位】：山西医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R742.5

【参考文献】